Sunburn, a clear indicator of overexposure to UV radiation, increases the risk of skin cancer. The estimated prevalence of sunburn in the United States is high; 37.1% of adults and 55.8% of youth reported 1 or more sunburns in the past 12 months.
Our study provides, to our knowledge, the first national estimates of sunburn-associated visits to US emergency departments, as well as their costs.
Methods | We analyzed data from the 2013 Nationwide Emergency Department Sample (NEDS) from the Healthcare Costs We estimated the annual number of sunburn-associated ED visits and associated costs. Often, the charges reported in the NEDS are greater than the amount reimbursed by payers. We therefore converted charges to costs using cost-to-charge ratios (CCRs) from the National Inpatient Sample, based on hospital accounting reports from the Centers for Medicare & Medicaid Services. 4 Given inadequate sample sizes for sunburn-associated inpatient stays, we used CCRs from all burn-associated inpatient stays. We calculated the cost of a sunburn-associated ED visit by multiplying the ED visit charge by the mean CCR of burnassociated inpatient stays, accounting for the hospital region, urban or rural location, and teaching status of the hospital. Sample weights were applied to provide national estimates. Data were analyzed using SUDAAN, version 10.1 (RTI International). Our analysis was exempted from the Centers for Disease Control and Prevention Institutional Review Board approval. Patient consent was not obtained as the data are from discharge information. Patient data are deidentified.
Results | Sunburn-associated ED visits were most frequent among youth and young adults, were evenly distributed by sex, occurred most frequently during the spring and summer months, and occurred most commonly in the South (Table) . In 2013, there were an estimated 33 826 sunburn-associated ED visits reported in the NEDS (after weighting), with an estimated total cost of $11.2 million ($5.5 million among males and $5.7 million among females). The largest number of visits and highest costs were among males younger than 18 years and females aged 18 to 29 years ( Figure) .
Discussion | Sunburn, a clear indication of overexposure to UV radiation, is a preventable risk factor for skin cancer, resulting in a considerable number of ED visits and substantial treatment costs. Although sunburn-associated ED visits have decreased from an estimated 40 826 in 2006 to 33 826 in 2013 (a 17.1% decrease), additional efforts are needed to reduce overexposure to UV radiation. Such efforts have gained momentum following the 2014 Surgeon General's Call to Action to Prevent Skin Cancer. 5, 6 Multicomponent community-wide interventions combining education and policy approaches to increase preventive behaviors (eg, seeking shade, using sunscreen, and wearing sun-protective clothing) have been demonstrated to reduce the incidence of sunburn. 5 In addition, for fair-skinned individuals aged 10 to 24 years, counseling about minimizing exposure to UV radiation is recommended by the US Preventive Services Task Force.
5
This analysis has limitations. First, the NEDS includes hospital charges rather than costs; however, we used accepted methods for estimating hospital costs from hospital charges using CCRs. Second, using mean inpatient CCRs to estimate ED visit costs may introduce error. Third, data were not available for additional patient demographics such as race/ethnicity. Finally, our cost estimates are underestimated because the NEDS includes only hospital facility charges, excludes physician and professional fees, and does not capture sunburns treated in other health care settings.
These nationally representative estimates demonstrate the substantial burden of sunburn-associated injuries and highlight the importance of continued monitoring of sunburn and sun-protective behaviors. Efforts to reduce overexposure to UV radiation could help reduce the substantial costs associated with sunburn-associated ED visits, as well as future cases of skin cancer. 
Follow-up on Programmed Cell Death 1 Inhibitor for Cutaneous Squamous Cell Carcinoma
Cutaneous squamous cell carcinoma (CSCC) is one of the 2 most common types of human malignant tumors.
1 Although most
CSCCs are effectively treated with excision, recurrent disease near vital structures or metastasis can be challenging to treat. Currently, there is no accepted standard of care for unresectable or metastatic CSCCs, although platinum compounds, taxanes, and fluorouracil are commonly used. Recently, 2 reports of CSCC cases treated with programmed cell death 1 (PD-1) inhibitors have been published but contain limited follow-up times (<7 months). 2, 3 The safety profile of PD-1 inhibitors in CSCCs is also not well known. We present 6 consecutive cases of advanced CSCCs treated with PD-1 inhibitors, including an extended follow-up of 1 previously reported index case 2 to 21 months of progression-free survival (PFS). Results | The index case, 2 previously published after 5 months of follow-up, is now reported after 21 months of PFS. Briefly, the patient is a white man in his 70s with a right temple CSCC with perineural invasion and subsequent recurrence necessitating multiple operations (including parotidectomy, lymph node dissections, and cranial nerve VII sacrifice with orbital exenteration), radiotherapy, and cetuximab treatment (Table and Figure) . The tumor was subsequently deemed unresectable because residual disease was discovered, extending up to the skull base adjacent to the basilar vascular system. The patient started pembrolizumab monotherapy with ongoing partial response at 21 months. His therapy was complicated by severe weakness attributable to hypocortisolism and hypothyroidism, which resolved with institution of systemic corticosteroids and thyroid hormone therapy. His additional adverse effects included mild arthralgia and mild weight loss. Additional cases are presented in the Table and Figure, including case 2, which involved a patient with a complete response. Of the 6 cases presented, the median age of the patients at CSCC diagnosis was 72.6 years (range, 60-82 years). All patients were immunocompetent.
Methods |
Five of 6 patients (83%) experienced a clinical response, with 1 complete and 4 partial responses. One patient (17%) had progressive disease. The median duration of PD-1 inhibitor exposure was 8 months (range, 3-21 months), and the longest PFS was 21 months. Two of 6 patients experienced severe adverse events, namely, fatigue caused by endocrine hypofunction and hip fracture, both of which were treated and resolved. The most common adverse effect was mild fatigue, seen in 5 patients (83%). None of the other adverse effects occurred in more than 1 patient.
Discussion | Current conventional chemotherapy treatment options for unresectable and metastatic cutaneous CSCCs remain limited. For instance, the largest retrospective study to date of 25 patients with high-risk CSCCs reported response rates of only 50% for locally advanced and 17% for metastatic CSCCs. The median PFS was only 5.5 months. 4 Although our data are from a case series and not a prospective clinical trial, they represent all the patients treated in our clinical practice with PD-1 inhibitors to date, with response rates and PFS exceeding the previous report. 4 Our report adds useful data to support the use of anti-PD-1 inhibitors for unresectable CSCCs, a finding that needs confirmation through larger clinical trials. In addition, all cases included in our series were in immunocompetent individuals. Because immunosuppressed individuals, including patients undergoing solid organ transplant, have an extremely high rate of CSCCs 5 and do poorly when treated with conventional chemotherapy, future studies are needed to determine whether PD-1 inhibitors may be beneficial for this population.
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